ArticleBMC molecular and cell biology2026
RBM39 upregulation promotes ostium re-obstruction after endoscopic endonasal dacryocystorhinostomy (En-DCR).
Article in BMC molecular and cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeChronic dacryocystitis, characterized by epiphora, is primarily treated with dacryocystorhinostomy (DCR), yet postoperative anastomotic re-obstruction remains a significant cause of failure. This study aimed to identify the key molecular mechanisms driving this recurrence.
methodsNasal mucosal tissues were collected from 30 post-DCR patients: 15 with re-obstruction (proliferation group) and 15 with successful outcomes (non-proliferation group). Proteomic analysis based on LC-MS/MS was conducted, with differentially expressed proteins (DEPs) defined by a fold change ≥ 1.5 and p < 0.05. Western blot and immunohistochemistry were used for validation and localization. The role of RBM39 in vascular endothelial cell proliferation was assessed via functional experiments, and its associated pathway was analyzed.
resultsProteomics identified RBM39 as significantly upregulated in re-obstruction tissues, confirmed to be expressed in the vascular endothelium. In vitro, RBM39 overexpression enhanced HMEC-1 proliferation, while its knockdown suppressed it. KEGG pathway analysis suggested the Focal Adhesion pathway may be involved as a potential downstream mechanism.
conclusionThis study observes that RBM39 is upregulated at the anastomotic site and correlates with enhanced vascular endothelial cell proliferation. The Focal Adhesion pathway may be implicated in this process, suggesting RBM39 as a candidate target for mitigating postoperative ostium re-obstruction after En-DCR. However, further mechanistic studies are needed to establish a direct causal relationship and evaluate its therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.